HAWKINS INC. - 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2008, and the nine-month period ended on the same date. Hawkins, Inc. is a Minnesota-based company operating in three reportable segments: Industrial, Water Treatment, and Pharmaceutical. The company manufactures and distributes bulk chemicals, water treatment products, and pharmaceutical ingredients.
Key Financial Metrics
Revenue and Profitability (Nine Months Ended Dec 31, 2008):
- Sales: $222,910,325 (up 53.5% from prior year).
- Gross Profit: $50,588,744 (22.7% margin).
- Income from Operations: $30,073,179 (13.5% margin).
- Net Income: $18,672,001 (8.4% margin).
- Earnings Per Share (Diluted): $1.82.
Liquidity and Balance Sheet:
- Cash and Cash Equivalents: $13,723,527 (down from $21.5M at March 30, 2008).
- Total Current Assets: $79,101,986.
- Total Current Liabilities: $27,613,509.
- Working Capital: $51,488,477.
- Debt: The filing does not disclose long-term debt obligations; the company relies on internally generated funds.
Cash Flow (Nine Months Ended Dec 31, 2008):
- Operating Cash Flow: $5,514,843 (decreased from $6.9M prior year due to working capital increases).
- Investing Cash Flow: $(8,175,448) (driven by $10.2M in capital expenditures).
- Financing Cash Flow: $(5,125,049) (primarily cash dividends paid).
Material Changes vs. Prior Period
Revenue Growth: Sales increased significantly across the Industrial and Water Treatment segments, driven by higher selling prices to offset rising material costs and increased demand amidst supply constraints. The Industrial segment sales rose $61.1M (9-month), while Water Treatment rose $17.4M.
Pharmaceutical Decline: Pharmaceutical segment sales decreased 12.4% (9-month) due to FDA restrictions on two major compounding chemicals and supply constraints.
Margin Expansion: Operating income margins improved substantially (from 7.5% to 13.5% for the 9-month period). This was driven by the sale of lower-cost inventory during a period of escalating commodity prices and improved operational efficiency, partially offset by a LIFO charge of $6.98M.
Capital Expenditures: Investing cash outflows increased significantly due to the acquisition of a 77,000 sq. ft. facility in Centralia, Illinois, and other capacity expansion projects.
Outlook, Risks, and Management Commentary
Management Commentary: Management attributes the strong performance to the company's inventory position, which allowed it to meet customer demand when competitors faced shortages. The company plans to spend approximately $8.0 million on capacity expansion for the current fiscal year, with $6.0 million already incurred.
Risks and Contingencies:
- Commodity Price Volatility: The company is subject to cyclical fluctuations in raw material costs. While they attempt to pass these costs to customers, there is no assurance they can do so in the future.
- Regulatory Actions: Ongoing FDA restrictions on specific pharmaceutical chemicals continue to impact that segment's sales.
- Investment Risk: The company holds fixed income securities subject to interest rate risk. Approximately $350,647 of investments were temporarily impaired but not considered other-than-temporarily impaired.
- Liquidity: While the company has no long-term debt, cash balances decreased due to heavy capital investment and dividend payments. Management believes internally generated funds are sufficient for future needs.
Investor Verification Checklist
- Verify the sustainability of the gross margin expansion given the LIFO charge and potential for raw material cost stabilization.
- Monitor the resolution of FDA restrictions on the Pharmaceutical segment and their impact on future revenue.
- Assess the return on investment for the $8.0M capacity expansion plan, specifically the new Centralia, Illinois facility.
- Review the aging of trade receivables, which increased by $7.8M, to ensure collectability in the current economic environment.
- Confirm the status of the temporarily impaired investments ($350k) to ensure they recover to cost basis as management intends.